We are live on ! Find out more
ARCT icon

Arcturus Therapeutics
ARCT

19 hedge funds and large institutions have $7.87M invested in Arcturus Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.44% more ownership

Funds ownership: 3.91% → 9.35% (+5.4%)

3% more capital invested

Capital invested by funds: $7.63M → $7.87M (+$239K)

21% less funds holding

Funds holding: 24 → 19 (-5)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

54% less call options, than puts

Call options by funds: $45K | Put options by funds: $98K

Holders
19
Holders Change
-5
Holders Change %
-20.83%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
3
Reduced
4
Closed
13
Calls
$45K
Puts
$98K
Net Calls
-$53K
Net Calls Change
-$43K

Top Buyers

1
AIM
ARK Investment Management
Florida
+$690K
2
OAM
Oxford Asset Management
United Kingdom
+$172K
3
ARTA
A.R.T. Advisors
New York
+$118K
4
JP Morgan Chase
JP Morgan Chase
New York
+$107K
5
VF
Virtu Financial
New York
+$97.2K

Top Sellers

1
KCM
Knoll Capital Management
Florida
-$812K
2
PAI
Palo Alto Investors
California
-$276K
3
PAM
Panagora Asset Management
Massachusetts
-$236K
4
KCM
Kingdon Capital Management
New York
-$128K
5
California Public Employees Retirement System
California Public Employees Retirement System
California
-$52K
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
1
Franklin Resources
California
$5.09M -$9 -1 -0%
RA
2
Royce & Associates
New York
$847K – – –
AIM
3
ARK Investment Management
Florida
$610K +$690K +76,737 New
WVP
4
Worth Venture Partners
New Jersey
$309K -$9 -1 -0%
Morgan Stanley
5
Morgan Stanley
New York
$271K -$21.9K -2,430 -7%
KCM
6
Kingdon Capital Management
New York
$226K -$128K -14,286 -33%
OAM
7
Oxford Asset Management
United Kingdom
$156K +$172K +19,137 New
ARTA
8
A.R.T. Advisors
New York
$128K +$118K +13,174 +440%
JP Morgan Chase
9
JP Morgan Chase
New York
$95K +$107K +11,899 New
VF
10
Virtu Financial
New York
$86K +$97.2K +10,811 New
Simplex Trading
11
Simplex Trading
Illinois
$17K +$19.1K +2,125 +1,864%
Parallax Volatility Advisers
12
Parallax Volatility Advisers
California
$15K +$17.1K +1,900 New
UBS Group
13
UBS Group
Switzerland
$9K +$1.49K +166 +17%
Group One Trading
14
Group One Trading
Illinois
$2K +$2.44K +271 New
Citigroup
15
Citigroup
New York
$1K – – –
Wells Fargo
16
Wells Fargo
California
$1K – – –
Barclays
17
Barclays
United Kingdom
$1K +$756 +84 New
KCM
18
Knoll Capital Management
Florida
– -$812K -114,864 Closed
PAI
19
Palo Alto Investors
California
– -$276K -38,970 Closed
PAM
20
Panagora Asset Management
Massachusetts
– -$236K -33,324 Closed
California Public Employees Retirement System
21
California Public Employees Retirement System
California
– -$52K -7,286 Closed
LCM
22
Leisure Capital Management
California
– -$22K -3,164 Closed
JMPWA
23
JP Morgan Private Wealth Advisors
California
– -$20K -2,857 Closed
FAM
24
Formidable Asset Management
Ohio
– -$14K -1,919 Closed
Goldman Sachs
25
Goldman Sachs
New York
– -$11K -1,615 Closed
1
2

ARCT Hedge Fund Activity: Q4 2017 in Review

19 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2017, worth a combined $7.87M — up 3.1% from $7.63M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ARCT and 9 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was ARK Investment Management, opening a new position worth an estimated $690K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $812K sold.

  • 19 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2017, down from 24 in Q3 2017.
  • Funds reported $7.87M of Arcturus Therapeutics stock for Q4 2017, up 3.1% quarter-over-quarter.
  • 9 funds opened new Arcturus Therapeutics positions in Q4 2017 and 13 closed out, a net change of -4 holders.
  • The largest Arcturus Therapeutics buyer in Q4 2017 was ARK Investment Management, an estimated $690K added.
  • The largest Arcturus Therapeutics seller in Q4 2017 was Knoll Capital Management, an estimated $812K sold.

Based on aggregated 13F filings for Q4 2017.